![qview health israel qview health israel](https://iuploads.scribblecdn.net/83ee8a58-a702-4ede-8a98-3b768cb03ff1/global/imagelib/lahey/lhmc_prm_logo_rgb-e8edd96b2b730c669d3e864c1f13bcd688418ff1.png)
However, BLES cannot be considered as a therapeutic device for small invasive breast carcinomas due to not achieving adequate excision. One technical complication occurred (retrieval of an empty BLES basket, specimen retrieved during subsequent surgery).ConclusionsBLES allows accurate diagnosis of small invasive breast carcinomas. Margin assessment was good for all BLES specimens. Margins were usually compromised on both sides of the specimen, indicating that the excised volume was too small.
![qview health israel qview health israel](https://images-vod.wixmp.com/eefef9ab-2055-4b96-9a2c-c8ca8d1de696/images/4289234f9c7841418287f1d5f4ccd231f001/v1/fill/w_800,h_450,q_85,usm_0.66_1.00_0.01/file.jpg)
None of the BLES excisions were adequate. Histopathological results were identical for the needle biopsy, BLES, and surgical specimens for all lesions. BLES revealed ten (90.9%) invasive carcinomas of no special type, and one (9.1%) invasive lobular carcinoma. Mean diameter of excised lesions at MRI was 11.8 mm (range 8.0-13.9 mm). The remaining 11 patients underwent BLES excision. Histopathology findings from the BLES procedure and surgery were compared, and total excision findings were assessed.ResultsOf the 22 patients, ten were excluded due to the lesion being > 15 mm and/or being multifocal at MRI, and one due to scheduling issues. BLES-based excision and surgery were performed during the same procedure. Patients underwent breast MRI to verify lesion size. PurposeTo assess the feasibility of completely excising small breast cancers using the automated, image-guided, single-pass radiofrequency-based breast lesion excision system (BLES) under ultrasound (US) guidance.Methodsįrom February 2018 to July 2019, 22 patients diagnosed with invasive carcinomas ≤ 15 mm at US and mammography were enrolled in this prospective, multi-center, ethics board-approved study.